Histogenics and MEDINET Sign Agreement for NeoCart in Japan

Histogenics (HSGX) entered into an agreement with MEDINET to develop and commercialize NeoCart® cell therapy in Japan. Terms include a US $10MM upfront payment to HSGX, with ~$77MM in potential milestones and future royalty payments. The activity supports HSGX's plans to expand its territories in Asia and Europe in 2018.

NeoCart is an autologous...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us